{"id":"https://openalex.org/W1993553202","doi":"https://doi.org/10.3310/hta6020","title":"Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment","display_name":"Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment","alternate_titles":[],"publication_year":2002,"publication_date":"2002-01-01","ids":{"openalex":"https://openalex.org/W1993553202","doi":"https://doi.org/10.3310/hta6020","mag":"1993553202","pmid":"https://pubmed.ncbi.nlm.nih.gov/12022937"},"language":"en","primary_location":{"id":"doi:10.3310/hta6020","doi":"https://doi.org/10.3310/hta6020","is_oa":true,"landing_page_url":"https://doi.org/10.3310/hta6020","pdf_url":"https://njl-admin.nihr.ac.uk/document/download/2004553","source":{"id":"https://openalex.org/S191206091","display_name":"Health Technology Assessment","issn_l":"1366-5278","issn":["1366-5278","2046-4924","2046-4932"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311817","host_organization_name":"NIHR Journals Library","host_organization_lineage":["https://openalex.org/P4310311817"],"host_organization_lineage_names":["NIHR Journals Library"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Health Technology Assessment","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1993553202"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://njl-admin.nihr.ac.uk/document/download/2004553","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067817683","display_name":"Christopher Hyde","orcid":"https://orcid.org/0000-0002-7349-0616","observed_orcids":["https://orcid.org/0000-0002-7349-0616"]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C. Hyde","raw_affiliation_strings":["Department of Public Health and Epidemiology, University of Birmingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Public Health and Epidemiology, University of Birmingham, UK","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009832867","display_name":"B. Wake","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"B. Wake","raw_affiliation_strings":["Department of Public Health and Epidemiology, University of Birmingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Public Health and Epidemiology, University of Birmingham, UK","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015667412","display_name":"Stirling Bryan","orcid":"https://orcid.org/0000-0001-7093-3058","observed_orcids":["https://orcid.org/0000-0001-7093-3058"]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. Bryan","raw_affiliation_strings":["The Health Economics Facility, Health Services Management Centre, University of Birmingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Health Economics Facility, Health Services Management Centre, University of Birmingham, UK","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070230058","display_name":"P Barton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"P. Barton","raw_affiliation_strings":["The Health Economics Facility, Health Services Management Centre, University of Birmingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Health Economics Facility, Health Services Management Centre, University of Birmingham, UK","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022963570","display_name":"Anne Fry-Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. Fry-Smith","raw_affiliation_strings":["Department of Public Health and Epidemiology, University of Birmingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Public Health and Epidemiology, University of Birmingham, UK","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081258369","display_name":"Clare F Davenport","orcid":"https://orcid.org/0000-0001-5659-4889","observed_orcids":["https://orcid.org/0000-0001-5659-4889"]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C. Davenport","raw_affiliation_strings":["Department of Public Health and Epidemiology, University of Birmingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Public Health and Epidemiology, University of Birmingham, UK","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041606201","display_name":"Fujian Song","orcid":"https://orcid.org/0000-0002-4039-1531","observed_orcids":["https://orcid.org/0000-0002-4039-1531"]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"F. Song","raw_affiliation_strings":["Department of Public Health and Epidemiology, University of Birmingham, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Public Health and Epidemiology, University of Birmingham, UK","institution_ids":["https://openalex.org/I79619799"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I79619799"],"apc_list":null,"apc_paid":null,"fwci":0.86,"has_fulltext":true,"cited_by_count":92,"citation_normalized_percentile":{"value":0.62411348,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"6","issue":"2","first_page":"1","last_page":"89"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fludarabine","display_name":"fludarabine","score":1.0},{"id":"https://openalex.org/keywords/b-cell-chronic-lymphocytic-leukaemia","display_name":"B-cell chronic lymphocytic leukaemia","score":0.8840000033378601},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.9629999995231628},{"id":"https://openalex.org/keywords/soluble-cd23","display_name":"soluble CD23","score":0.8830000162124634},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.3370000123977661},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.6000000238418579}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8565099239349365},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.8066835403442383},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.5305526852607727},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3938716948032379},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35606372356414795},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3428512215614319},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34217411279678345},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.23331290483474731},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.21166738867759705},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001853","descriptor_name":"Bone Marrow","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001853","descriptor_name":"Bone Marrow","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006113","descriptor_name":"United Kingdom","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013673","descriptor_name":"Technology Assessment, Biomedical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014740","descriptor_name":"Vidarabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014740","descriptor_name":"Vidarabine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D014740","descriptor_name":"Vidarabine","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D014740","descriptor_name":"Vidarabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017281","descriptor_name":"Cost of Illness","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.3310/hta6020","doi":"https://doi.org/10.3310/hta6020","is_oa":true,"landing_page_url":"https://doi.org/10.3310/hta6020","pdf_url":"https://njl-admin.nihr.ac.uk/document/download/2004553","source":{"id":"https://openalex.org/S191206091","display_name":"Health Technology Assessment","issn_l":"1366-5278","issn":["1366-5278","2046-4924","2046-4932"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311817","host_organization_name":"NIHR Journals Library","host_organization_lineage":["https://openalex.org/P4310311817"],"host_organization_lineage_names":["NIHR Journals Library"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Health Technology Assessment","raw_type":"journal-article"},{"id":"pmid:12022937","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12022937","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Health technology assessment (Winchester, England)","raw_type":"Journal Article"},{"id":"pmh:oai:ueaeprints.uea.ac.uk:12946","doi":null,"is_oa":false,"landing_page_url":"https://ueaeprints.uea.ac.uk/id/eprint/12946/","pdf_url":null,"source":{"id":"https://openalex.org/S4306400384","display_name":"UEA Digital Repository (University of East Anglia)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1118541","host_organization_name":"University of East Anglia","host_organization_lineage":["https://openalex.org/I1118541"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Article"},{"id":"pmh:oai:doaj.org/article:048506489f7f4db39496acb3e9b9640d","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/048506489f7f4db39496acb3e9b9640d","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Health Technology Assessment, Vol 6, Iss 2 (2002)","raw_type":"article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/bc5bed01-d35a-462b-8142-325656248b3a","doi":null,"is_oa":false,"landing_page_url":"https://research.birmingham.ac.uk/en/publications/bc5bed01-d35a-462b-8142-325656248b3a","pdf_url":null,"source":{"id":"https://openalex.org/S4306402634","display_name":"University of Birmingham Research Portal (University of Birmingham)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79619799","host_organization_name":"University of Birmingham","host_organization_lineage":["https://openalex.org/I79619799"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hyde, C, Wake, B, Bryan, S, Barton, P, Fry-Smith, A, Davenport, C & Song, F 2002, 'Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment', Health Technology Assessment, vol. 6, no. 2, pp. 1-89.","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3310/hta6020","doi":"https://doi.org/10.3310/hta6020","is_oa":true,"landing_page_url":"https://doi.org/10.3310/hta6020","pdf_url":"https://njl-admin.nihr.ac.uk/document/download/2004553","source":{"id":"https://openalex.org/S191206091","display_name":"Health Technology Assessment","issn_l":"1366-5278","issn":["1366-5278","2046-4924","2046-4932"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311817","host_organization_name":"NIHR Journals Library","host_organization_lineage":["https://openalex.org/P4310311817"],"host_organization_lineage_names":["NIHR Journals Library"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Health Technology Assessment","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G5358830265","display_name":null,"funder_award_id":"00/12/01","funder_id":"https://openalex.org/F4320319990","funder_display_name":"National Institute for Health and Care Research"},{"id":"https://openalex.org/G8453750176","display_name":null,"funder_award_id":"00/12/01","funder_id":"https://openalex.org/F4320334661","funder_display_name":"Health Technology Assessment Programme"}],"funders":[{"id":"https://openalex.org/F4320319990","display_name":"National Institute for Health and Care Research","ror":"https://ror.org/0187kwz08"},{"id":"https://openalex.org/F4320334661","display_name":"Health Technology Assessment Programme","ror":"https://ror.org/0187kwz08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1993553202.pdf","grobid_xml":"https://content.openalex.org/works/W1993553202.grobid-xml"},"referenced_works_count":55,"referenced_works":["https://openalex.org/W65919465","https://openalex.org/W103174640","https://openalex.org/W154103547","https://openalex.org/W338104690","https://openalex.org/W1501443642","https://openalex.org/W1599621040","https://openalex.org/W1635565950","https://openalex.org/W1862276309","https://openalex.org/W1939111644","https://openalex.org/W1965851569","https://openalex.org/W1971245246","https://openalex.org/W1973279572","https://openalex.org/W1973556880","https://openalex.org/W1984544099","https://openalex.org/W1986215651","https://openalex.org/W2017270639","https://openalex.org/W2020827660","https://openalex.org/W2025334762","https://openalex.org/W2041143246","https://openalex.org/W2082253535","https://openalex.org/W2093523596","https://openalex.org/W2095799532","https://openalex.org/W2098254065","https://openalex.org/W2103929079","https://openalex.org/W2116248495","https://openalex.org/W2119928026","https://openalex.org/W2123528154","https://openalex.org/W2130434229","https://openalex.org/W2130842355","https://openalex.org/W2135806859","https://openalex.org/W2155104760","https://openalex.org/W2183329523","https://openalex.org/W2183434481","https://openalex.org/W2187693705","https://openalex.org/W2229733741","https://openalex.org/W2257284526","https://openalex.org/W2317888977","https://openalex.org/W2337089158","https://openalex.org/W2399754510","https://openalex.org/W2400556262","https://openalex.org/W2406321134","https://openalex.org/W2408885152","https://openalex.org/W2409914821","https://openalex.org/W2412839075","https://openalex.org/W2419468745","https://openalex.org/W2462438592","https://openalex.org/W2528301896","https://openalex.org/W2883739273","https://openalex.org/W2916663880","https://openalex.org/W4238310152","https://openalex.org/W4241041535","https://openalex.org/W4290218571","https://openalex.org/W4290699400","https://openalex.org/W4292123111","https://openalex.org/W4407828941"],"related_works":["https://openalex.org/W7019322908","https://openalex.org/W2158373508","https://openalex.org/W2339386715","https://openalex.org/W7028744905","https://openalex.org/W2467573159","https://openalex.org/W2528128155","https://openalex.org/W2001306122","https://openalex.org/W1953903051","https://openalex.org/W2484073494","https://openalex.org/W4239665277"],"abstract_inverted_index":{"A":[0],"peer":[1],"reviewer":[2],"notes":[3],"that":[4,16],"use":[5],"of":[6],"soluble":[7],"CD23":[8],"levels":[9],"in":[10],"the":[11],"UK":[12],"is":[13],"rare":[14],"and":[15],"much":[17],"greater":[18],"emphasis":[19]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1993553202","counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
